” Based on the strong results for the first nine months of 2021, higher growth in the GLP-1 market and an expected increase in sales of obesity treatments in the US, we have increased our outlook for both sales and profit growth in 2021. Lars Fruergaard Jørgensen, president & CEO 3/2021 • SHARE Magazine 5
Download PDF file